FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
FDA
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
FDA approves belzutifan with lenvatinib for advanced renal cell carcinoma
The FDA approved belzutifan in combination with lenvatinib for advanced clear cell renal cell carcinoma.